Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AbCellera plans to present Phase 1/2 ABCL635 data at TMS 2026 on Oct. 22, including safety, pharmacokinetics, pharmacodynamics and preliminary efficacy. The presentation will include new Phase 1 multiple ascending dose safety data and new Phase 2 patient-reported outcomes.
AbCellera said it will present Phase 1/2 data on ABCL635 at The Menopause Society's 2026 Annual Meeting in San Diego later this month. The poster will include new safety and patient-reported outcome data from the company's Phase 1 and Phase 2 studies.
AbCellera announces presentation of Phase 1/2 data for ABCL635 at the TMS 2026 Annual Meeting.
AbCellera said it will hold a poster presentation of Phase 1/2 data for ABCL635 at The Menopause Society’s 2026 Annual Meeting on Oct. 20-24 in San Diego.